$ 1157.83
Key Takeaways
Risk factor
Negligible price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Excellent growth
Data is available to registered users only
Data is available to registered users only
In Guru Portfolios
About
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,
Data is available to registered users only
Target Price
The average target price of LLY is 1273 and suggests 8.52% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
Data is available to registered users only